Simcere Pharmaceutical Group Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 6,584

Employees

  • Stock Symbol
  • 02096

Stock Symbol

  • Investments
  • 17

  • Share Price
  • $1.10
  • (As of Friday Closing)

Simcere Pharmaceutical Group General Information

Description

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Contact Information

Website
www.simcere.com
Formerly Known As
Jiangsu Cuccess Pharmaceutical, Innovent Biologics
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Number 699-18, Xuanwu Avenue
  • Nanjing, Jiangsu 210042
  • China
+86 025
Primary Industry
Pharmaceuticals
Stock Exchange
HKG
Vertical(s)
Corporate Office
  • Number 699-18, Xuanwu Avenue
  • Nanjing, Jiangsu 210042
  • China
+86 025

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Simcere Pharmaceutical Group Stock Performance

As of 25-Apr-2025, Simcere Pharmaceutical Group’s stock price is $1.10. Its current market cap is $2.72B with 2.47B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.10 $1.13 $0.65 - $1.17 $2.72B 2.47B 6.53M $0.04

Simcere Pharmaceutical Group Financials Summary

As of 31-Dec-2024, Simcere Pharmaceutical Group has a trailing 12-month revenue of $925M.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 1,990,304 1,990,304 2,074,991 3,769,344
Revenue 924,709 924,709 933,981 939,052
EBITDA 165,544 165,544 145,478 169,936
Net Income 102,177 102,177 101,028 138,223
Total Assets 1,576,681 1,576,681 1,531,144 1,563,775
Total Debt 165,665 165,665 201,623 218,391
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Simcere Pharmaceutical Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Simcere Pharmaceutical Group‘s full profile, request access.

Request a free trial

Simcere Pharmaceutical Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on
Pharmaceuticals
Nanjing, China
6,584 As of 2024

Pune, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Simcere Pharmaceutical Group Competitors (1)

One of Simcere Pharmaceutical Group’s competitors is Emcure Pharmaceuticals, a Formerly PE-Backed company based in Pune, India.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Emcure Pharmaceuticals Formerly PE-Backed Pune, India
You’re viewing 1 of 1 competitors. Get the full list »

Simcere Pharmaceutical Group Patents

Simcere Pharmaceutical Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4365183-A1 Steroid compound, and pharmaceutical composition thereof and use thereof Pending 24-Jun-2021
US-20240307415-A1 Steroid compound, and pharmaceutical composition thereof and use thereof Pending 24-Jun-2021
JP-2024523545-A Steroid compounds, pharmaceutical compositions thereof and their applications Pending 24-Jun-2021
US-20240084003-A1 Anti-human cd22 monoclonal antibodies and use thereof Pending 18-Jan-2021
US-20240076403-A1 Her2 antibody and application thereof Pending 18-Dec-2020 C07K16/32
To view Simcere Pharmaceutical Group’s complete patent history, request access »

Simcere Pharmaceutical Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Simcere Pharmaceutical Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Simcere Pharmaceutical Group‘s full profile, request access.

Request a free trial

Simcere Pharmaceutical Group Investments (17)

Simcere Pharmaceutical Group’s most recent deal was a Later Stage VC with AnDiConBio for . The deal was made on 30-Apr-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AnDiConBio 30-Apr-2024 Later Stage VC Drug Discovery
Tobishi Pharmaceutical 07-Apr-2024 Corporate Therapeutic Devices
AnDiConBio 08-Nov-2023 Later Stage VC Drug Discovery
NeuroDawn Pharmaceutical 06-Feb-2023 Early Stage VC Drug Discovery
Carmine Therapeutics 29-Nov-2022 Early Stage VC Biotechnology
You’re viewing 5 of 17 investments. Get the full list »

Simcere Pharmaceutical Group ESG

Risk Overview

Risk Rating

Updated October, 15, 2024

32.01 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Pharmaceuticals

Subindustry

of 430

Rank

Percentile

To view Simcere Pharmaceutical Group’s complete esg history, request access »

Simcere Pharmaceutical Group Exits (3)

Simcere Pharmaceutical Group’s most recent exit was on 23-Dec-2019 from 3D Medicines. The exit was categorized as with 6 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
3D Medicines 23-Dec-2019 Completed
  • 6 buyers
I-Mab Biopharma 30-Jun-2016 Completed
  • 2 buyers
Shanghai Celgen Biopharma 01-Aug-2009 Corporate Completed
To view Simcere Pharmaceutical Group’s complete exits history, request access »

Simcere Pharmaceutical Group Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
Simcere Zaiming Haikou, China 2020
Simcere Nanjing, China 2017
Jilin Boda pharmaceutical Liaoyuan, China 1995

Simcere Pharmaceutical Group FAQs

  • When was Simcere Pharmaceutical Group founded?

    Simcere Pharmaceutical Group was founded in 1995.

  • Where is Simcere Pharmaceutical Group headquartered?

    Simcere Pharmaceutical Group is headquartered in Nanjing, China.

  • What is the size of Simcere Pharmaceutical Group?

    Simcere Pharmaceutical Group has 6,584 total employees.

  • What industry is Simcere Pharmaceutical Group in?

    Simcere Pharmaceutical Group’s primary industry is Pharmaceuticals.

  • Is Simcere Pharmaceutical Group a private or public company?

    Simcere Pharmaceutical Group is a Public company.

  • What is Simcere Pharmaceutical Group’s stock symbol?

    The ticker symbol for Simcere Pharmaceutical Group is 02096.

  • What is the current stock price of Simcere Pharmaceutical Group?

    As of 25-Apr-2025 the stock price of Simcere Pharmaceutical Group is $1.10.

  • What is the current market cap of Simcere Pharmaceutical Group?

    The current market capitalization of Simcere Pharmaceutical Group is $2.72B.

  • What is Simcere Pharmaceutical Group’s current revenue?

    The trailing twelve month revenue for Simcere Pharmaceutical Group is $925M.

  • Who are Simcere Pharmaceutical Group’s competitors?

    Emcure Pharmaceuticals is a competitor of Simcere Pharmaceutical Group.

  • What is Simcere Pharmaceutical Group’s annual earnings per share (EPS)?

    Simcere Pharmaceutical Group’s EPS for 12 months was $0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »